Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) EBT (2022 - 2025)

Historic EBT for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$10.8 million.

  • Pharmaceuticals' EBT fell 2802.46% to -$10.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 4919.66%. This contributed to the annual value of -$38.1 million for FY2024, which is 4400.44% down from last year.
  • Per Pharmaceuticals' latest filing, its EBT stood at -$10.8 million for Q2 2025, which was down 2802.46% from -$10.1 million recorded in Q1 2025.
  • Pharmaceuticals' EBT's 5-year high stood at -$3.3 million during Q4 2023, with a 5-year trough of -$14.9 million in Q4 2022.
  • Over the past 4 years, Pharmaceuticals' median EBT value was -$7.8 million (recorded in 2023), while the average stood at -$8.1 million.
  • Data for Pharmaceuticals' EBT shows a peak YoY increase of 7782.11% (in 2023) and a maximum YoY decrease of 4622.12% (in 2023) over the last 5 years.
  • Over the past 4 years, Pharmaceuticals' EBT (Quarter) stood at -$14.9 million in 2022, then surged by 77.82% to -$3.3 million in 2023, then tumbled by 156.48% to -$8.5 million in 2024, then fell by 28.02% to -$10.8 million in 2025.
  • Its last three reported values are -$10.8 million in Q2 2025, -$10.1 million for Q1 2025, and -$8.5 million during Q2 2024.